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Abstract
Up to 10% of women take selective serotonin reuptake inhibitors (SSRI) during pregnancy. Chil-
dren exposed to SSRIs in utero have an increased risk of being overweight suggesting that fetal
exposure to SSRIs can cause permanent metabolic changes. We have previously shown in rats
that fetal and neonatal exposure to the SSRI antidepressant fluoxetine results in metabolic per-
turbations including increased hepatic triglyceride content; a hallmark of non‐alcoholic fatty liver
disease (NAFLD). Therefore, the aim of this study was to identify the mechanism(s) underlying the
fluoxetine‐induced increase in intrahepatic triglyceride content. Female nulliparous Wistar rats
were given vehicle or fluoxetine (10 mg/kg/day) orally for 2 weeks prior to mating until weaning.
At 6 months of age, we assessed whether SSRI exposure altered components of the hepatic tri-
glyceride biosynthesis pathway in the offspring and examined the molecular mechanisms under-
lying these changes. Male SSRI‐exposed offspring had a significant increase in the steady‐state
mRNA levels of Elovl6 and Dgat1 and core components of the NLRP3 inflammasome (apopto-
sis‐associated speck‐like protein containing a caspase activation recruitment domain [ASC] and
caspase‐1). Augmented expression of Asc in the SSRI‐exposed offspring coincided with increased
histone acetylation in the proximal promoter region. Given that we have previously demonstrated
that antenatal exposure to SSRIs can lead to fatty liver in the offspring, this raises concerns
regarding the long‐term metabolic sequelae of fetal SSRI exposure. Moreover, this study suggests
that elevated hepatic triglyceride levels observed in the SSRI‐exposed offspring may be due, in
part, to activation of the NLRP3 inflammasome and augmentation of de novo lipogenesis.
KEYWORDS
developmental origins of disease, dyslipidemia, histone acetylation, inflammasome, metabolic
syndrome, non‐alcoholic fatty liver disease, post‐translational histone modifications, selective
serotonin reuptake inhibitors, triglycerides
1 | INTRODUCTION
Depression is currently estimated to affect as many as 840 million peo-
ple worldwide (World Health Organization, 2008). Women of child-
bearing age appear to be particularly susceptible both to new onset
depressive illness and the exacerbation of existing depression (Burt &
Stein, 2002; Noble, 2005). This vulnerability is particularly pronounced
during the perinatal period. Indeed, the reported prevalence of perina-
tal depression ranges from 6.5% to 25% (Gavin et al., 2005; Gelaye,
Rondon, Araya, & Williams, 2016). If left untreated, maternal depres-
sion has been linked to poor maternal and obstetrical outcomes
(Gelaye et al., 2016; Grote et al., 2010; Marcus, 2009) and can have
long‐lasting deleterious effects on cognitive, behavioral and psycho-
logical development in the offspring (Stein et al., 2014). As a result,
up to one in 10 women use antidepressants during pregnancy
(Andrade et al., 2008; Cooper, Willy, Pont, & Ray, 2007; Huybrechts
et al., 2013). The most common antidepressants used during preg-
nancy are the selective serotonin reuptake inhibitors (SSRI); however,
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their long‐term safety in the offspring remain elusive (Andrade et al.,
2008; Muzik & Hamilton, 2016; Smith et al., 2008; Trifirò et al.,
2013; Wemakor, Casson, & Dolk, 2014).
In children and adults the long‐term use of SSRIs is associated with
increased weight gain, dyslipidemia and new‐onset type 2 diabetes
(Jerrell, 2010; Yoon, Cho, Lee, & Park, 2013; Schwartz et al., 2016;).
As the fetus and neonate can be exposed to SSRIs via placental and
lactational transfer (Rampono et al., 2009), it is plausible that SSRI
use during pregnancy may also cause similar metabolic disturbances
in the exposed offspring. In support of this hypothesis, Grzeskowiak
et al. (2013) reported that male offspring exposed prenatally to an SSRI
had an increased risk of being overweight by 7 years of age. Similarly,
our lab has demonstrated in a rodent model that fetal and neonatal
exposure to the SSRI antidepressant fluoxetine results in metabolic
perturbations in adulthood including increased adiposity and insulin
resistance (De Long et al., 2015). Moreover, fluoxetine exposure
resulted in increased hepatic triglyceride content; a hallmark of non‐
alcoholic fatty liver disease (NAFLD) (De Long et al., 2015).
NAFLD is often associated with obesity and insulin resistance and
is one of the most common chronic liver diseases worldwide
(Bellentani, 2017). It encompasses a spectrum of stages which includes
simple steatosis, non‐alcoholic steatohepatitis (NASH; steatosis with
evidence of hepatic inflammation with or without fibrosis) and cirrho-
sis (Tiniakos, Vos, & Brunt, 2010). Accumulation of hepatic
intracytoplasmic triglycerides is a key component of all stages of
NAFLD (Tiniakos et al., 2010) and stems from an imbalance between
lipid uptake, synthesis (i.e., de novo lipogenesis), utilization (i.e., fatty
acid oxidation) and export (Tiniakos et al., 2010). Complex
radiolabeling studies in humans have identified that an increase in de
novo lipogenesis plays a significant role in intrahepatic triglyceride
accumulation and the pathogenesis of NAFLD (Diraison, Moulin, &
Beylot, 2003; Donnelly et al., 2005; Softic, Cohen, & Kahn, 2016). In
vitro studies have demonstrated that fluoxetine augments lipid accu-
mulation in hepatocytes in association with upregulation of genes crit-
ical for de novo lipogenesis (Feng et al., 2012; Xiong et al., 2014). This
would suggest that the observed increase in hepatic triglycerides in flu-
oxetine‐exposed offspring could be due to dysregulation of the same
pathway (De Long et al., 2015). In addition to increased hepatic triglyc-
eride accumulation, enhanced de novo lipogenesis also modifies fatty
acid composition in the liver which in turn can lead to the development
of NASH (Duwaerts & Maher, 2014). The mechanism(s) underlying the
progression of NAFLD to NASH are not well understood, but recent
evidence from human studies and rodent models suggests that the
NOD‐like receptor family, pryin domain containing 3 (NLRP3)
inflammasome may play a key role (Wan, Xu, Yu, & Li, 2016).
The NLRP3 inflammasome is a large intracellular multiprotein
complex consisting of nod‐like receptor protein 3 (NLRP3), apopto-
sis‐associated speck‐like protein containing a caspase activation
recruitment domain (ASC) and pro‐caspase 1 (Schroder & Tschopp,
2010). Activation of NLRP3 induces caspase‐1 expression and the sub-
sequent maturation of pro‐interleukin‐1β (pro‐IL1β) and pro‐interleu-
kin‐18 (pro‐IL18) into their active forms (Jo, Kim, Shin, & Sasakawa,
2016; Schroder & Tschopp, 2010). There is now convincing evidence
that hepatic lipid accumulation is associated with increased expression
and activation of the NLRP3 inflammasome (De Nardo & Latz, 2011;
Haneklaus & O'Neill, 2015). Moreover, in animal models, activation
of the NLRP3 inflammasome has been shown to play a role in the pro-
gression of NAFLD to NASH (reviewed in [Wan et al., 2016]). This is of
great interest as we have reported that fetal and neonatal exposure to
fluoxetine increased the proportion of offspring with mild‐to‐moderate
NASH (De Long et al., 2015). Moreover, as fluoxetine has been shown
to increase production of IL1β (Alboni et al., 2016), which is mainly
dependent on activation of the NLRP3 inflammasome (Martinon,
Burns, & Tschopp, 2002), these data suggest that the increased preva-
lence of NASH in offspring born to fluoxetine‐exposed dams may be a
result of dysregulated de novo lipogenesis and activation of the NLRP3
inflammasome. Hence, the present study was designed to investigate
the effects of fetal and neonatal exposure to fluoxetine on the tran-
scriptional and epigenetic regulation of genes involved in hepatic de
novo lipid synthesis and the NLRP3 inflammasome.
2 | MATERIALS AND METHODS
2.1 | Maintenance and treatment of animals
All animal experiments were approved by the Animal Research Ethics
Board at McMaster University, in accordance with the guidelines of
the Canadian Council for Animal Care. Nulliparous 200‐250 g female
Wistar rats (Harlan, Indianapolis, Indiana) were conventionally housed
in polycarbonate microisolator cages under controlled lighting
(12:12 L:D), humidity (40–50%), and temperature (22°C) with ad
libitum access to water and standard chow diet (Teklad 22/5 rodent
diet; Envigo, Indianapolis, Indiana). Dams were randomly assigned to
receive vehicle (CON; N = 15) or 10 mg/kg/day fluoxetine hydrochlo-
ride (FLX; N = 15; Toronto Research Chemicals, Toronto, Ontario)
orally in flavored gelatin cubes from 14 days prior to mating until
weaning (postnatal day 21; PND21) as previously described (De Long
et al., 2015). The dose of fluoxetine was chosen based on previous
studies (Capello et al., 2011; Hui, Huang, Ebbert, & Bina, 2007) to
achieve serum fluoxetine levels in the rat which are representative of
the median serum concentration of fluoxetine (i.e., 450 nmol/L)
reported in humans (Olivier et al., 2011; Sit, Perel, Helsel, & Wisner,
2008). Dams were allowed to deliver normally. At birth (PND1), pups
were weighed and sexed and litters were culled to 8, preferentially
selecting 4 male and 4 female offspring, to ensure uniformity of litter
size between treated and control litters. Offspring were maintained
on a chow diet until 26 weeks of age. We have previously reported
that these offspring have increased hepatic triglyceride content,
hepatic inflammation and an increase prevalence of NASH (De Long
et al., 2015). At 26 weeks of age, one male offspring per litter was
fasted overnight, euthanized by CO2 asphyxiation and liver tissue
was collected and snap frozen in liquid nitrogen for subsequent ana-
lyzes. Only male offspring were analyzed in this study to prevent the
confounding effects caused by the female reproductive cycle.
2.2 | Transcriptional regulation of de novo
lipogenesis and NLRP3 inflammasome
To examine the effects of fetal and neonatal exposure to fluoxetine
on de novo lipogenesis we performed qPCR to determine the
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steady‐state mRNA expression of key enzymes responsible for the
synthesis of triglycerides (acetyl‐CoA carboxylase [Acc1], fatty acid
synthase [Fasn], stearoyl CoA desaturase 1 [Scd1], ELOVL family mem-
ber 6, elongation of very long fatty acid [Elovl6], and diacylglycerol
acyltransferase 1 and 2 [Dgat1, Dgat2]). We also determined the
steady‐state mRNA levels of the core components of the NLRP3
inflammasome; nod‐like receptor protein 3 (Nlrp3), apoptosis‐
associated speck‐like protein containing a caspase activation recruit-
ment domain (Asc) and caspase‐1 (Casp1).
Total RNA was isolated from male 26‐week liver tissue using
TRIzol® (Life Technologies, Grand Island, New York) extraction
combined with the RNeasy® mini kit (Qiagen, Hilden, Germany)
(N = 9–10 animals per treatment group). Complementary DNA
(cDNA) was synthesized from 2 μg of RNA using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City,
California) according to the manufacturer's instructions using Per-
feCta® SYBR® green FastMix® (Quanta Biosciences, Gaithersburg,
Maryland) on the LightCycler480 (Roche, Mississauga, Ontario). The
cycling conditions included polymerase activation (95°C for
10 min), followed by 40 cycles of denaturing (95°C for 15 s) and
annealing/elongation (60°C for 1 min). The cycle threshold was set
so that exponential increases in amplification were approximately
level between all samples. Given all primer sets had equal priming
efficiency, the ΔCt values for each primer set were obtained accord-
ing to Livak and Schmittgen (2001), by normalizing gene expression
to calibrated to two housekeeping genes (hypoxanthine‐guanine
phosphoribosyltransferase [Hprt] and Cyclophilin A [Cyc]). The aver-
age of all control Ct values, and the relative abundance of each
primer set compared with calibrator was determined by the formula
2ΔΔCt, in which ΔΔCt was the normalized value. Primer sequences
are supplied in Table 1.
2.3 | Epigenetic regulation of de novo lipogenesis
and NLRP3 inflammasome
2.3.1 | Histone extraction
Liver tissue collected from male offspring at 26 weeks of age was
ground using a mortar and pestle and resuspended in in lysis buffer
(10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, and protease
cocktail inhibitor [Roche]). Hydrochloric acid was added to a final con-
centration of 0.2 M. The resultant solution was then sonicated at 30%
amplitude for 5 s total, 1 s per pulse, and incubated on ice for 30 min
with periodic vortexing. It was then centrifuged at 11 000 g for
10 min at 4°C. The supernatant was collected and underwent dialysis
using Pierce Slide‐A‐Lyzer MINI Dialysis Units (3500 MWCO)
(ThermoFisher Scientific, Burlington, Ontario, Canada). The order of
dialysis occurred in the following manner: 2 × 200 mL of 0.1 M acetic
acid for 1 h, 200 mL of deionized water for 1 h, 200 mL of deionized
water for 3 h, and 200 mL of water overnight. Samples were then
stored at −80°C until further analysis.
2.3.2 | Global histone acetylation
In total, 10 μg of total histone proteins were loaded and subjected to
12% SDS‐PAGE and transferred to a polyvinylidene difluoride (PVDF)
blotting membrane (BioRad Laboratories, Hercules, California). Mem-
branes were blocked for 3 h in 5% (wt/vol) skim milk inTTBS (Tris‐buff-
ered saline [TBS], 0.1% [vol/vol] Tween 20) at room temperature on a
rocking platform and then incubated with Histone H3 (cat #05–499;
MilliporeSigma, Etobicoke, Ontario, Canada) and acetylated histone
H3 [K9,14] (cat #sc‐06‐599; MilliporeSigma) primary antibody at 4°C
overnight. After washing with TTBS, blots were incubated with perox-
idase‐conjugated secondary anti‐rabbit or anti‐mouse antibody
(1:5000; GE Healthcare, QC, California) for 1 h at room temperature
on a rocking platform. Blots were developed using enhanced chemilu-
minescence (ECL) (MilliporeSigma) and quantification was carried out
using ImageLab 4.1 software (ImageLab Version 4.1 build 16; Bio‐
Rad, Hercules, California). Immunoblots were subsequently incubated
with stripping buffer (ThermoFisher Scientific) and re‐probed with β‐
actin (1:4,000; Abcam, Toronto, Ontario, Canada) to control for protein
loading. Histone H3 and acetylated histone H3 [K9,14] was normalized
to β‐actin. Data presented are the ratio of acetylated histone H3
[K9,14]:Total histone H3.
2.3.3 | Chromatin immunoprecipitation (ChIP)
Chromatin was extracted from liver tissues excised at 26 weeks of age
from male offspring as previously described (Sohi, Marchand, Revesz,
Arany, & Hardy, 2011). In brief, a small piece of snap frozen liver was
homogenized and incubated in 0.5 mL of 1% formaldehyde for
10 min at room temperature to cross‐link proteins and DNA. Glycine
(0.125 M, final concentration) was added to all samples to terminate
cross‐linking. Samples were micro centrifuged at 950 g at room tem-
perature for 5 min and supernatant was subsequently removed. The
liver tissue was then washed once with cold phosphate‐buffered saline
before being placed in 500 μL of DS lysis buffer (MilliporeSigma) with
TABLE 1 Real‐time PCR rat primers used in the study
Gene Forward primer Reverse primer Genebank accession #
Acc1 ATTGGGCACCCCAGAGCTA CCCGCTCCTTCAACTTGCT NM_022193.1
Asc TGGTTTGCTGGATGCTCTGT CACGAACTGCCTGGTACTGT NM_172322.1
Casp1 AACACCCACTCGTACACGT TGAGGTCAACATCAGCTCCG NM_012762.2
Dgat1 CAGACCAGCGTGGGCG GAACAAAGAGTCTTGCAGACGATG NM_053437.1
Dgat2 GGAACCGCAAAGGCTTTGTA AATAGGTGGGAACCAGATCAGC NM_001012345.1
Elovl6 GGTCGGCATCTGATGAACAAG CGAATATACTGAAGACCGCAAGAG NM_134383.2
Nlrp3 CACAACTCACCCAAGGAGGA ACAGGCAACATGAGGGTCTG NM_001191642.1
Scd1 CTGACCTGAAAGCTGAGAAG ACAGGCTGTGCAGGAAAGTT NM_139192.2
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protease inhibitor cocktail (Roche). Each sample was sonicated to pro-
duce sheared, soluble chromatin. The lysates were diluted 10 times
with the addition of ChIP dilution buffer (MilliporeSigma) and aliquoted
to 300 μL amounts. Each of the aliquots was precleared with protein
A/G Plus agarose beads (40 μL; MilliporeSigma) and rotated for 2 h
at 4°C. To pellet the beads, samples were micro centrifuged at
20 000 g, and the supernatant containing the sheared chromatin was
placed in new tubes. The aliquots were incubated with 3 μg of acety-
lated histone H3 antibody (lysine 9,14, cat #05–399; MilliporeSigma)
and rotated overnight at 4°C. Two aliquots were reserved as
‘controls’ — one incubated without anti‐ body (‘input’) and another
with non‐immune IgG (MilliporeSigma). Protein A/G Plus agarose
beads (60 μL) were added to each tube, the mixtures rocked for 1 h
at 4°C and the immune complexes collected by centrifugation. The
beads containing the immunoprecipitated complexes were washed
sequentially for 5 min in wash buffer I (20 mM Tris–HCl, pH 8.1,
2 mM EDTA, 0.1% SDS, 1% Tri‐ ton X‐100, 150 mM NaCl), wash
buffer II (same as I, except containing 500 mM NaCl), wash buffer III
(10 mM Tris–HCl, pH 8.1, 1 mM EDTA, 1% NP‐40, 1% deoxycholate,
0.25 M LiCl) and in 2 × TE buffer. The beads were eluted with
250 μL elution buffer (1% SDS, 0.1 mM NaHCO3 + 20 μg salmon
sperm DNA [Sigma‐Aldrich, Oakville, Ontario, Canada]) at room tem-
perature. The elution step was repeated once and eluates were com-
bined. Crosslinking of the immunoprecipitated chromatin complexes
and ‘input controls’ (10% of the total soluble chromatin) was reversed
by heating the samples at 65°C for 4 h. Pro‐ teinase K (15 μg
[Invitrogen, Carlsbad, California]) was added to each sample in buffer
(50 mM Tris–HCl, pH 8.5, 1% SDS, 10 mM EDTA) and incubated for
1 h at 45°C. The DNA was purified by phenol‐chloroform extraction
and precipitated in ethanol overnight at −20°C. The supernatant was
removed and pellets were dried. Both samples and ‘input’ controls'
were diluted in 10–100 μL TE buffer prior to PCR analysis.
TABLE 2 Real‐time PCR rat ChIP primers used in the study
Gene Forward primer Reverse primer Genebank accession #
Asc TGGAAGAGGGTGGAGTCCTG CCGCGGTCACCTTTTACTCT NM_012762
Casp1 ACTCGGTACATGTGCCTCAC AAAGGAGCAGGGAAACGATGT NM_012762
Elovl6 CCCACATGAGGGAAAGAGAG CCAGCCCCACAGGTTTTT NP_599210.1
Nlrp3 AACTGTGCCAGTCTATGGGG CTTAGATCCACGCTGGCAGA NM_001191642
FIGURE 1 The effect of fetal and neonatal fluoxetine exposure on hepatic steady‐state mRNA levels of Acc1, Fasn, Scd1, Elovl6, Dgat1 and Dgat2
in male rat offspring at 26 weeks of age. Data are presented as fold change from the controls and results are expressed as the mean ± SEM. Values
marked with an asterisk (*) are significantly (P < 0.05) different from controls (N = 9–10 per experimental group)
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Quantitative real‐time PCR was employed using primers against
the proximal rat promoters of Asc (−155 to +13), Nlrp3 (−180 to
−50), Casp1 (−155 to −62) and Elovl6 (−293 to −186) (Table 2;
PE Applied Biosystems, Boston, Massachusetts). The transcriptional
start sites (TSS) of each gene was found using the Ensembl
Genome Browser (http://www.ensembl.org). The aforementioned
constructed ChIP primers were then used in conjunction with
Sso‐Fast EvaGreen Supermix (Bio‐Rad, Mississauga, Ontario) to per-
form qRT‐PCR. Using serial dilutions of rat liver chromosomal DNA,
the primers were demonstrated to have good linear correlation
(slope ~ 3.4), suggesting equal priming efficiency in priming to their
target sequence. Similar to the gene expression assays, the relative
abundance of the immunoprecipitated chromatin compared to input
chromatin was determined using the 2ΔΔCt method. The relative
abundance of each primer set compared with calibrator was deter-
mined by the formula, 2Δ ΔCt, in which ΔΔCt is the calibrated Ct
value.
2.4 | Statistical analysis
All statistical analyzes were performed using SigmaStat (v.3.1; SPSS,
Chicago, Illinois). The results are expressed as the mean ± SEM. The
results from quantitative RT‐PCR, immunoblot and ChIP analysis are
expressed as the mean of arbitrary values ± SEM. Outcome measures
between male control and fluoxetine‐treated offspring were analyzed
using Student's t‐test (α = 0.05). Data were tested for normality as well
as equal variance, and when normality or variance tests failed, data
were analyzed using the Mann–Whitney rank sum test.
3 | RESULTS
3.1 | De novo lipogenesis
To elucidate the molecular mechanisms underlying the previously
reported inflammation, elevated hepatic triglyceride levels, and NASH
in fluoxetine‐exposed male adult rat offspring, we examined the
expression of key enzymes in de novo triglyceride production in the
liver. In 26‐week male fluoxetine‐exposed offspring, quantitative
real‐time PCR revealed increases in the hepatic expression of Elovl6,
Dgat1 and Dgat2, enzymes involved in the terminal steps of triglycer-
ide synthesis, although the change in Dgat2 expression did not reach
statistical significance (P = 0.06). In contrast, the expression of Acc1,
Fasn, and Scd1, important enzymes for the initial stages of triglyceride
synthesis were not significantly altered by early life exposure to fluox-
etine (Figure 1).
FIGURE 2 The effect of fetal and neonatal fluoxetine exposure on global and promoter‐specific hepatic histone H3 [K9,14] acetylation in male rat
offspring at 26 weeks of age. Data are presented as A, Densitometry of acetylated histone H3 [K9,14] to total histone H3, and B, ChIP analysis of
relative histone H3 [K9,14] immunoprecipitated genomic DNA levels normalized to total genomic DNA. Results are expressed at the mean ± SEM.
Values marked with an asterisk (*) are significantly (P < 0.05) different from controls (N = 6–8 per experimental group)
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3.2 | Epigenetic regulation of de novo lipogenesis
To explore whether fetal and neonatal fluoxetine exposure had any
effect on post‐translational histone modifications, we first investigated
whether there were any global changes in total hepatic acetylated his-
tone H3 lysine 9 [K9,14] in the offspring of fluoxetine‐treated dams at
26 weeks of age. Immunoblotting revealed there was a significant
increase in the global acetylation of H3 lysine 9 [K9,14] in the isolated
histones from the livers of fluoxetine‐exposed offspring at 26 weeks
(Figure 2A).
Epigenetic posttranslational histone modifications such as
increased histone H3 acetylation [K9,14], promoting chromatin open-
ing, lead to transcriptional activation (Lee et al., 1993). Therefore, we
next employed chromatin immunoprecipitation (ChIP) to determine
whether this increased acetylation of histone H3 was associated, in a
promoter‐specific manner, with the observed increased transcription
of Elovl6 and/or Dgat1. Although there was a trend (P = 0.09) for fluox-
etine‐exposed offspring to have higher H3 acetylation at the Elovl6
promoter, there was no significant difference in the histone H3 acety-
lation in the proximal promoter of either gene (Figure 2B and C).
3.3 | Increase in hepatic Elovl6 expression is
associated with a corresponding increase in the steady
state mRNA levels of core components of the NLRP3
inflammasome in fluoxetine exposed offspring
In animal models, hepatic triglyceride accumulation has been associ-
ated with activation of the NLRP3 inflammasome (Yang, Lee, & Lee,
2016). Interestingly, overexpression of Elovl6 in mouse hepatocytes
has also been shown to upregulate the steady‐state mRNA expression
of NLRP3, ASC and caspase‐1, core components of the NLRP3
inflammasome (Matsuzaka et al., 2012). Moreover, the product of
Elovl6, stearate, has been demonstrated to activate the NLRP3
inflammasome in macrophages (L'homme et al., 2013). Therefore, we
next employed real‐time PCR to determine whether or not the
increase in Elovl6 in fluoxetine‐exposed offspring was associated with
evidence of enhanced NLRP3 inflammasome expression. Despite the
almost fivefold difference in NLRP3 mRNA expression between con-
trol and fluoxetine exposed offspring, this did not reach statistical sig-
nificance (P = 0.10). However, fluoxetine exposure did result in a
significant (P ≤ 0.05) upregulation of the steady state mRNA levels of
the other core components of the NLRP3 inflammasome, ASC and
caspase‐1 (Figure 3).
3.4 | Augmented expression of ASC coincides with
increased histone acetylation in the promoter region
To investigate if chromatin remodeling could be a factor influencing
the observed increases in NLRP3, ASC and caspase‐1 steady‐state
mRNA levels after early life exposure to fluoxetine, we employed ChIP
to assess histone H3 [K9,14] acetylation in the promoters of these
genes. ChIP revealed that in the 26‐week livers of fluoxetine‐exposed
offspring there was significant enrichment in histone H3 [K9,14]
acetylation surrounding the proximal promoter of Asc but not Nlrp3
or Casp1 (Figure 4).
4 | DISCUSSION
NAFLD is a major cause of liver disease worldwide, with an estimated
global prevalence of approximately 25% (Younossi et al., 2016). It is a
non‐reversible condition which is characterized by hepatic steatosis,
in particular, an accumulation of intrahepatic triglycerides (Tiniakos
et al., 2010). Approximately 10–20% of patients with NAFLD go on
to develop NASH which is characterized by steatosis plus hepatic
inflammation and/or fibrosis (Tilg & Moschen, 2010). Although the
increasing global burden of NAFLD has significant implications for
public health and health care expenditures, the pathophysiology of
FIGURE 3 The effect of fetal and neonatal fluoxetine exposure on
hepatic steady‐state mRNA levels of Nlrp3, Casp1 and Asc in male rat
offspring at 26 weeks of age. Data are presented as fold change from
the controls and results are expressed as the mean ± SEM. Values
marked with an asterisk (*) are significantly (P < 0.05) different from
controls (N = 9–10 per experimental group)
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NAFLD is not completely understood. However, increasing evidence
from animal models suggest that chemical insults during fetal and neo-
natal development, including maternal smoking and ethanol consump-
tion, lead to an increased risk of NAFLD in postnatal life (Lynch, Chan,
& Drake, 2017). Similarly, work from our group has reported that fetal
and neonatal exposure to fluoxetine leads to NAFLD in the offspring
(De Long et al., 2015). Given that approximately 6% of pregnant
women in the United States are prescribed SSRIs during pregnancy
(Andrade, Reichman, Mott, & Pitts, 2016), this highlights the impor-
tance of understanding the effects of these medications on the risk
of NAFLD in the offspring.
Accumulation of hepatic intracytoplasmic triglycerides is a key
component of NAFLD (Tiniakos et al., 2010) and results from an imbal-
ance between lipid uptake, synthesis, utilization and export (Tiniakos
et al., 2010). However, data from humans have shown that increased
de novo lipogenesis may be the critical factor in the development of
NAFLD (Diraison et al., 2003; Donnelly et al., 2005; Lambert, Ramos‐
Roman, Browning, & Parks, 2014; Softic et al., 2016). In our animal
model, fetal and neonatal exposure to fluoxetine increased hepatic tri-
glyceride content without a concomitant increase in circulating triglyc-
eride levels (De Long et al., 2015). Moreover, cell culture studies have
revealed that fluoxetine treatment increases genes critical for de novo
lipogenesis (Feng et al., 2012; Xiong et al., 2014). Taken together,
these data suggested that the observed increase in hepatic triglycer-
ides in this perinatal exposure model might be mediated by upregula-
tion of de novo lipogenesis. Indeed, results from the current study
supported this hypothesis; steady‐state mRNA levels of Elovl6 and
Dgat1 were elevated in the liver of male fluoxetine‐exposed offspring
at 26 weeks of age.
Elovl6 is an enzyme responsible for catalyzing the elongation of
unsaturated and monounsaturated fatty acid chains C:12‐C:18
(Jakobsson, Westerberg, & Jacobsson, 2006) whereas Dgat1 catalyzes
the terminal step in triglyceride synthesis (Liu, Siloto, Lehner, Stone, &
Weselake, 2012). In mouse models, over‐expression of both Dgat1 and
Elovl6 has been reported to result in increased hepatic triglyceride con-
tent (Matsuzaka et al., 2012; Monetti et al., 2007). Similarly, in our
model the increased expression of Elovl6 and Dgat1 in fluoxetine‐
exposed offspring occurred in concert with increased liver triglyceride
content (De Long et al., 2015). Moreover, in mice, overexpression of
Elovl6 but not Dgat1 was associated with hepatic inflammation
(Monetti et al., 2007; Matsuzaka et al., 2012;). Collectively, these data
suggest that increased expression of hepatic Elovl6 may play a key role
in etiology of NASH in fluoxetine‐exposed offspring. Further support
for this hypothesis comes from a human study where hepatic Elovl6
mRNA expression was increased in patients with NASH compared to
control subjects (Matsuzaka et al., 2012). The mechanisms linking
FIGURE 4 The effect of fetal and neonatal fluoxetine exposure on inflammasome promoter‐specific hepatic histone H3 [K9,14] acetylation in male
rat offspring at 26 weeks of age. Data are presented as ChIP analysis of relative histone H3 [K9,14] immunoprecipitated genomic DNA levels
normalized to total genomic DNA. Results are expressed at the mean ± SEM. Values marked with an asterisk (*) are significantly (P < 0.05) different
from controls (N = 6–8 per experimental group)
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increased hepatic Elovl6 expression to NASH have not been fully elu-
cidated, but evidence from animal and cell culture models suggests
that it may involve the NLRP3 inflammasome.
Expression of NLRP3 and its key components have been shown to
be increased in rodents and humans with NASH (Wan et al., 2016).
Moreover, pharmacological inhibition of the NLRP3 inflammasome
suppressed high‐fat diet‐induced hepatic steatosis (Yang et al., 2016),
implicating that this is a causal relationship. In contrast, overexpression
of Elovl6 in mice activated the NLRP3 inflammasome (Matsuzaka et al.,
2012). Similarly, in our study increased Elovl6 mRNA expression in flu-
oxetine‐exposed animals was associated with increased expression of
NLRP3, ASC and caspase‐1, although the increase in NLRP3 did not
reach statistical significance (P = 0.10). Taken together these data are
consistent with a link between dysregulation of Elovl6, activation of
the NLRP3 inflammasome and NASH in fluoxetine‐exposed offspring.
However, it is noteworthy that the increase in core components of the
hepatic NLRP3 inflammasome after early life exposure to fluoxetine
animals is at odds with studies in adult animals where fluoxetine has
been shown to directly inhibit NLRP3 inflammasome activity in periph-
eral macrophages, microglia and the prefrontal cortex (Du et al., 2016;
Pan, Chen, Zhang, & Kong, 2014). Whether this is related to the timing
of exposure or represents a tissue‐specific effect remains to be deter-
mined. To further explore the underlying molecular mechanisms by
which early life exposure to fluoxetine could affect de novo lipogenesis
and/or the NLRP3 inflammasome, we decided to investigate the role
of epigenetic modifications in our model.
There is now considerable evidence to suggest that chemical
insults during perinatal development can increase the risk of metabolic
syndrome in the postnatal life via alterations in the epigenome (Desai,
Jellyman, & Ross, 2015). These epigenetic modifications can include
altered DNAmethylation, histone modifications, chromatin remodeling
and/or changes in microRNAs. Maternal fluoxetine exposure has been
shown to result in posttranslational histone modifications and altered
DNA methylation in the offspring (Boulle et al., 2016; Toffoli et al.,
2014). There is also some evidence in the literature that demonstrates
epigenetic regulation of Elovl6 and core components of NLRP3
inflammasome (Corominas et al., 2015; Meier, Drexler, Eberle, Lefort,
& Yazdi, 2016; Tang et al., 2016). Moreover, knockdown of sirtuin 1
(SIRT1), a NAD+‐dependent deacetylase has been demonstrated to
enhance activation of the NLRP3 inflammasome in HUVEC cells (Li
et al., 2017) and inhibition of SIRT1 in hepatocytes results in an upreg-
ulation of de novo lipogenesis related genes (Nassir & Ibdah, 2016).
Taken together these data suggest that post‐translational histone
modifications may also represent an important pathway by which early
life exposure to fluoxetine can increase the risk of NASH. Remarkably,
we demonstrated that fetal and neonatal exposure to fluoxetine
results in increased global acetylated histone H3 in the liver of male
offspring at 26 weeks of age. Despite no changes in histone H3 acet-
ylation [K9,14] in the promoters of Elovl6, Dgat, Nlrp3 or Casp1, the
increase in Asc expression was concomitant with enhanced histone
H3 acetylation [K9,14] at surrounding its proximal promoter region
which would promote transcriptional activation. This is of great inter-
est considering epigenetic regulation of Asc appears to be key factor
for the activation of the inflammasome complex. For example, a study
in human cutaneous squamous cell carcinoma reported that promoter
specific methylation of Asc led to a decrease in its expression concom-
itant with impaired activation of the NLRP3 inflammasome (Meier
et al., 2016). Therefore it is tempting to speculate that increased
expression of Asc also plays a key role in the development of hepatic
inflammation in our model, although evidence for a causal relationship
remains to be further explored.
In summary, we have shown for the first time that fetal and neo-
natal exposure to fluoxetine increases hepatic expression of Elovl6
and core components of the NLRP3 inflammasome which may explain,
in part, the increased prevalence of NASH in these animals. However,
it is impossible to determine from the present study whether this phe-
notype was present from the time of exposure or whether there was
latency in its onset. Regardless, given the widespread usage of these
drugs during pregnancy, these results suggest that evaluation of meta-
bolic outcomes in children exposed to SSRI antidepressants during
fetal and neonatal life warrants further study.
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